From Yahoo Finance · · 1m 10s
AbbVie Dividend King Standout?
AbbVie's 54-year dividend streak and patent resilience make it a top pick for income-focused investors despite industry risks.
In brief
AbbVie's 54-year dividend streak and patent resilience make it a top pick for income-focused investors despite industry risks. AbbVie maintains strong dividend growth and innovation pipeline after Humira patent loss, offering reliable income with long-term resilience. Originally reported by Yahoo Finance.
54-Year Dividend Streak
AbbVie has raised dividends for 54 consecutive years since splitting from Abbott Laboratories in 2013.
“Including the time AbbVie spent under the wing of its former parent company, it has increased its payouts for 54 consecutive years.”
Humira Patent Cliff Impact
Humira lost U.S. patent exclusivity in 2023, but AbbVie quickly rebounded with revenue growth through new products.
“This immunology medicine lost patent exclusivity in the U.S. in 2023.”
Allergan Acquisition
AbbVie's $63 billion acquisition of Allergan added Botox and other key products to its portfolio.
“The company's biggest deal was the $63 billion acquisition of Allergan, which granted it access to several key products, including the Botox franchise.”
Rinvoq and Skyrizi Growth
Rinvoq and Skyrizi are AbbVie's fastest-growing immunology products with patent exclusivity extending through the 2030s.
“These two immunology products are now its biggest growth drivers.”
Future Drug Pipeline
AbbVie has promising candidates like ABBV-295 for weight loss and ABBV-706 for cancer in late-stage trials.
“Acquired products, such as Zumilokibart, a promising investigational medicine for eczema, could meaningfully contribute down the line if they succeed in phase 3 studies.”
Dividend King Debate
Some investors avoid pharmaceuticals due to patent cliffs and regulatory risks, but AbbVie's track record shows resilience.
“For these people, a drugmaker like AbbVie is out of the question, regardless of how well it is performing right now.”
Stock Advisor Note
The Motley Fool's Stock Advisor team did not recommend AbbVie despite its strong dividend history.
“The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them.”
The big picture
AbbVie maintains strong dividend growth and innovation pipeline after Humira patent loss, offering reliable income with long-term resilience.
